Curcumin-Artemisinin Combination Therapy for Malaria

Dalavaikodihalli Nanjaiah Nandakumar,† Viswanathan Arun Nagaraj,† Palakkod Govindan Vathsala,† Pundi Rangarajan, and Govindarajan Padmanaban*

Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India

Received 22 December 2005/Returned for modification 24 January 2006/Accepted 30 January 2006

Artemisinin and curcumin show an additive interaction in killing Plasmodium falciparum in culture. In vivo, 3 oral doses of curcumin following a single injection of α,β-arteether to Plasmodium berghei-infected mice are able to prevent recrudescence due to α,β-arteether monotherapy and ensure almost 100% survival of the animals.

Artemisinin derivative-based combination therapy (ACT) has been advocated as the therapy of choice to handle widespread drug resistance in Plasmodium falciparum malaria, at the same time preventing recrudescence due to artemisinin monotherapy. However, most of the combinations are less than ideal because of side effects, pharmacokinetic mismatch, and cost (8, 15). Studies in this laboratory have shown that curcumin isolated from the roots of Curcuma longa (turmeric) has antimalarial activity in P. falciparum culture and in Plasmodium berghei-infected mice (10). In this study, we propose a novel artemisinin-curcumin therapy to treat malaria.

Artemisinin and curcumin (98% curcuminoid content) were purchased from Sigma Chemicals, Bangalore, India. α,β-Arteether (EMAL, a synthetic derivative of artemisinin) developed by Central Drug Research Institute, Lucknow, India, was a kind gift from IPCA Laboratories Ltd., Mumbai, India. [3H]hypoxanthine was purchased from Perkin-Elmer, Singapore.

The P. falciparum FCK strain, a local chloroquine-resistant isolate, was cultured in human O-positive washed erythrocytes using standard protocols (14). Parasites were synchronized using 5% (wt/vol) D-sorbitol, and the cultures were pooled and the parasites released from the erythrocyte with 0.15% (wt/vol) saponin (3) for further processing. The 50% inhibitory concentrations (IC50s) for artemisinin and curcumin were determined in P. falciparum cultures by measuring [3H]hypoxanthine uptake into the parasite as a measure of viability (2). Fractional inhibitory concentrations (FIC) were calculated using the formula

\[ \frac{A_C + B_C}{A_E + B_E} \]

where \( A_C \) and \( B_C \) are the concentrations of \( A \) and \( B \) in the combination associated with a particular level of effect, e.g., IC90, and \( A_E \) and \( B_E \) are the concentrations of \( A \) and \( B \) when used singly to produce the same level of effect, on the basis that a simple additive interaction should lead to a value of 1 (7).

Means ± standard deviations and Student’s \( t \) test were analyzed using Microsoft Excel.

For in vivo studies, Swiss mice (25 to 28 g) were injected intraperitoneally with P. berghei-infected mouse blood (60 to 70% parasitemia) on day 0, such that the animals developed high parasitemia and died in about 5 to 8 days. The artemisinin derivative α,β-arteether was injected intramuscularly at different doses on day 1. This was followed by oral feeding of curcumin in dimethyl sulfoxide on days 1, 2, and 3 (100 mg/kg of body weight). The mice were observed for external symptoms and mortality when the drugs were given alone or in combination. Blood from the tail vein was analyzed on different days for parasitemia using Giemsa to stain the slides.

Detailed studies indicate that the IC50s for artemisinin and curcumin are 45 to 50 nM and 15 to 18 µM, respectively. On this basis, several combinations of artemisinin and curcumin were used to generate dose-response curves, and the data were used to calculate the FIC. The results presented in Table 1 indicate that the FIC at all the ICs tested are <1, and the results are statistically significant. The values are >0.5, and the interaction between curcumin and artemisinin in P. falciparum culture would be termed nonsynergistic (7).

The efficacy of the curcumin-artemisinin combination in P. falciparum culture led us to evaluate its efficacy in vivo. The results presented in Fig. 1 indicate that α,β-arteether or curcumin monotherapy at the indicated doses prolongs the survival of P. berghei-infected mice (25 to 28 g) but does not confer complete protection. Thus, while the P. berghei-infected animals die between 5 to 7 days, a single injection of α,β-arteether at 500 µg, 750 µg, and 1.5 mg results in the death of animals between 9 to 11, 16 to 18, and 32 to 34 days, respectively. However, treatment of the infected mice with a combi-

<table>
<thead>
<tr>
<th>Inhibition level</th>
<th>FIC (mean ± SD)*</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IC50</td>
<td>0.81 ± 0.06</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>IC75</td>
<td>0.79 ± 0.05</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>IC80</td>
<td>0.83 ± 0.06</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>IC90</td>
<td>0.78 ± 0.07</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

*FIC obtained are statistically lower than 1, the value indicative of additive interaction.

† These authors made equal contributions to this study.

* Corresponding author. Mailing address: Department of Biochemistry, Indian Institute of Science, Bangalore 560 012, India. Phone and fax: 91 080 23601492. E-mail: geepee@biochem.iisc.ernet.in.

‡ These authors made equal contributions to this study.
The injection of a single dose of arteether at 750 µg or 1.5 mg per infected mouse led to complete protection of animals against recrudescence and 100% survival.

The artemisinin derivative-based combinations under development are artesunate plus amodiaquine, artesunate plus sulfadoxine-pyrimethamine, artesunate plus mefloquine, dihydroartemisinin plus piperaquine, and artemether plus lumefantrine (8). Artesunate plus mefloquine is well tolerated and highly effective. It has been used in Thailand for almost a decade (9).

The artemether plus lumefantrine combination is the only formulation that has been registered for use in Africa, although a study has shown irreversible hearing impairment (13). The combination also needs fat for better absorption (15). A general issue with many of these combinations is side effects and pharmacokinetic mismatch between artemisinin and the other drugs in the combination. Another major concern of all these combinations is their high cost.

The curcumin-artemisinin combination may prove superior from several perspectives. Both are from natural sources of long-term use, and as such, no resistance is known to curcumin that is present in a dietary supplement. Artemisinin runs the risk of resistance development when used widely as monotherapy (5). Curcumin is tolerated at very high doses, and as much as 8 g/day has been given for 3 months to cancer patients on trial without toxic side effects (1). A single dose of 750 µg of arteether in the curcumin combination that gives complete protection in P. berghei-infected mice, when extrapolated to the human dose (8), would work out to nearly one-third of the dose recommended for the artemisinin-lumefantrine combination in the patients. Thus, there is potential to decrease the dose of artemisinin and lower the cost of therapy. Curcumin itself is a cheap compound. It is interesting to note the effectiveness of curcumin in combination with α,β-arteether, although curcumin is reported to manifest low bioavailability and rapid metabolism in rodents and humans (6). In a sense, the rapid clearance of artemisinin (12) and curcumin (6) overcomes the problem of pharmacokinetic mismatch. However, if necessary, strategies are available to increase the bioavailability of curcumin in humans. For example, a low dose of piperine from pepper can enhance curcumin uptake by 2,000% in humans, and the combination is well tolerated (11). In view of all these characteristics, the artemisinin derivative-curcumin combination is worth serious consideration for trial in humans.

This study was supported by grants from the Department of Biotechnology, New Delhi, India.

REFERENCES